Automated High-Definition MRI Processing Routine Robustly Detects Longitudinal Morphometry Changes in Alzheimer's Disease Patients

Simon Rechberger; Yong Li; Sebastian J Kopetzky; Markus Butz-Ostendorf; Alzheimer’s Disease Neuroimaging Initiative

doi:10.3389/fnagi.2022.832828

Automated High-Definition MRI Processing Routine Robustly Detects Longitudinal Morphometry Changes in Alzheimer's Disease Patients

Front Aging Neurosci. 2022 Jun 7:14:832828. doi: 10.3389/fnagi.2022.832828. eCollection 2022.

Authors

Simon Rechberger¹, Yong Li², Sebastian J Kopetzky^{2

3}, Markus Butz-Ostendorf^{2

4}; Alzheimer’s Disease Neuroimaging Initiative

Affiliations

¹ Viscovery Software GmbH, Vienna, Austria.
² Biomax Informatics, Munich, Germany.
³ School of Life Sciences, Technical University of Munich, Freising, Germany.
⁴ Parallel Programming, Department of Computer Science, Technical University of Darmstadt, Darmstadt, Germany.

Abstract

Longitudinal MRI studies are of increasing importance to document the time course of neurodegenerative diseases as well as neuroprotective effects of a drug candidate in clinical trials. However, manual longitudinal image assessments are time consuming and conventional assessment routines often deliver unsatisfying study outcomes. Here, we propose a profound analysis pipeline that consists of the following coordinated steps: (1) an automated and highly precise image processing stream including voxel and surface based morphometry using latest highly detailed brain atlases such as the HCP MMP 1.0 atlas with 360 cortical ROIs; (2) a profound statistical assessment using a multiplicative model of annual percent change (APC); and (3) a multiple testing correction adopted from genome-wide association studies that is optimally suited for longitudinal neuroimaging studies. We tested this analysis pipeline with 25 Alzheimer's disease patients against 25 age-matched cognitively normal subjects with a baseline and a 1-year follow-up conventional MRI scan from the ADNI-3 study. Even in this small cohort, we were able to report 22 significant measurements after multiple testing correction from SBM (including cortical volume, area and thickness) complementing only three statistically significant volume changes (left/right hippocampus and left amygdala) found by VBM. A 1-year decrease in brain morphometry coincided with an increasing clinical disability and cognitive decline in patients measured by MMSE, CDR GLOBAL, FAQ TOTAL and NPI TOTAL scores. This work shows that highly precise image assessments, APC computation and an adequate multiple testing correction can produce a significant study outcome even for small study sizes. With this, automated MRI processing is now available and reliable for routine use and clinical trials.

Keywords: HCP MMP 1.0; SBM; VBM; clinical trials; dementia; longitudinal surface based morphometry; longitudinal voxel based morphometry; neurodegeneration.